ICON plc

development of drugs and devices that save lives

Hybrid

Some members of the team work remotely, while others are co-located in one or more offices.

💼Healthcare

👥10,000+

📍Dublin

ICON plc

About ICON plc

ICON plc help our clients to accelerate the development of drugs and devices

What ICON plc is building

delivering best in class information, solutions and performance, with an unyielding focus on quality at all times

Technologies used at ICON plc

Front-end (3)

Back-end (3)

HTML

CSS

Angular

Funding rounds

Company type

For Profit

ICON plc news and updates

ICON plc launches 2021 ESG report

ICON has published its 2021 ESG report, which shows the strong progress Mapi Group has made against its ESG priorities and commitments.

Sep 11, 2022 | iconplc.com

ICON plc receives award 2021 CRO Leadership Awards

ICON received 2021 CRO Leadership Awards in the five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall.

Jan 1, 2022 | iconplc.com

ICON plc recognized as Company of the Year at 2021 Business & Finance Irish Business Awards and Pharma Contract Services Company of the Year at the Pharma Industry Awards 2021 on Apr 1st 22'.

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been recognised with a number of prestigious business and industry awards in April 2022, including Company of the Year at the 2021 Business & Finance Irish Business Awards and Pharma Contract Services Company of the Year at the Pharma Industry Awards 2021.

Jan 1, 2022 | businesswire.com

ICON plc recognized as Compatibility (Big Pharma) category at CRO Leadership Awards

ICON is honoured to have been recognised in the Compatibility (Big Pharma) category in the annual CRO Leadership Awards.